Nuvation Bio Inc. is a global oncology company focused on developing and commercializing therapies for cancer. Founded in 2018, the company commercially launched IBTROZI (taletrectinib) in the U.S. in June 2025 for ROS1+ non-small cell lung cancer. Its pipeline also includes safusidenib, a brain-penetrant mIDH1 inhibitor in Phase 3 development, and a preclinical drug-drug conjugate (DDC) platform.
expected 2026-11-05
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001193125-26-085584 | EDGAR | 104K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034903 | EDGAR | 96K words |
| 2024-02-29 | 2023-12-31 | 0000950170-24-023247 | EDGAR | 74K words |
| 2023-03-15 | 2022-12-31 | 0000950170-23-008180 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002332 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001193125-21-077880 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-336646 | EDGAR | 77K words |
| 2025-11-03 | 2025-09-30 | 0001193125-25-262605 | EDGAR | 77K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104626 | EDGAR | 76K words |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065712 | EDGAR | 69K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122402 | EDGAR | 69K words |
| 2024-08-05 | 2024-06-30 | 0000950170-24-090347 | EDGAR | 68K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059622 | EDGAR | 59K words |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058253 | EDGAR | 52K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-038155 | EDGAR | 52K words |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017926 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021943 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014868 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-336751 | EDGAR | 6K words |
| 2026-03-02 | 0001193125-26-085474 | EDGAR | 5K words |
| 2026-01-12 | 0001193125-26-009826 | EDGAR | 6K words |
| 2025-11-26 | 0001193125-25-298551 | EDGAR | 6K words |
| 2025-11-17 | 0001193125-25-284845 | EDGAR | 6K words |
| 2025-11-03 | 0001193125-25-262576 | EDGAR | 5K words |
| 2025-08-07 | 0001193125-25-174954 | EDGAR | 5K words |
| 2025-06-11 | 0001193125-25-139164 | EDGAR | 5K words |
| 2025-05-23 | 0001193125-25-125763 | EDGAR | 1K words |
| 2025-05-07 | 0001193125-25-114908 | EDGAR | 3K words |
92 total filings indexed. 64 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001811063 |
| Ticker | NUVB |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nuvationbio.com |
| Listed | 2021-02-10 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NUVB (~200 tokens, structured JSON with cryptographic provenance)